A large-scale phase 3 study shows that Merck's Gardasil 9 vaccine protects against HPV-related cancers for at least six years.

Researchers in England are kicking off the world's first large human trial of a "universal" influenza shot.

After a major cancer vaccine misstep, Bavarian Nordic reported positive six-week data from an ongoing phase 2 study on its RSV vaccine candidate.

Inovio and GeneOne have started a clinical study of their MERS vaccine in South Korea, where the virus took 36 lives in a 2015 outbreak.

Secretive Moderna shared a new peek into its infectious disease vaccines efforts Thursday.

A phase 3 study shows that Seqirus' MF59-adjuvanted quadrivalent flu vaccine provides better protection in those younger than two years old.

PATH, Walter Reed and GSK have partnered to determine whether tweaking the regimen of Mosquirix could lead to better malaria protection.

Themis secured £3 million from Innovate UK for its Chikungunya vaccine project.